to reduce the risk of sustained estimated GFR (eGFR) decline, ESRD, and CV death in patients with type 2 diabetes mellitus and chronic kidney disease Ozempic and Rybelsus tablets: To reduce the risk of major CV events in patients with type 2 diabetes mellitus who are at high risk for these events Wegovy (injection and tablets): In combination with a reduced calorie diet and increased physical activity, to reduce the risk of major adverse CV events in patients with established CV disease and either obesity or overweight Usual Adult Dose for Renal Risk Reduction Ozempic Injection: Initial dose: 0.25 mg subcutaneously once a week for 4 weeks, then 0.5 mg subcutaneously once a week Maintenance dose: After at least 4 weeks on the 0.5 mg dose, increase to 1 mg subcutaneously once a week
It comes as a tablet (Rybelsus) or an injection (Ozempic) and is available on the NHS
After losing 50 lb, that mechanical demand drops substantially
This includes progress monitoring, dosing adjustments when appropriate, and access to providers through the platform's secure messaging system
While it was originally used to treat type 2 diabetes, it is also very effective for obesity when a patient needs to lose weight to improve their overall health
